Suven Pharma arm Hyderabad facility gets USFDA EIR

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-09-09T11:15:02+05:30 | Updated On 9 Sept 2024 3:54 PM IST

Maharashtra: Suven Pharma has announced that Casper Pharma Private Limited, a Wholly Owned Subsidiary of the Company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the formulations manufacturing facility located in Hyderabad.

The US FDA has categorized the inspection as "Voluntary Action Indicated" (VAI) and has deemed it as "closed" under 21 CFR 20.64(d)(3).

Voluntary action indicated (VAI) means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Medical Dialogues team had earlier reported that the USFDA had issued 2 observations for the Casper Pharma Private Limited in Hyderabad, a WOS of the company

Read also: Casper Pharma gets 2 USFDA observations

suven pharmasuven pharma newsUSFDAcasper pharmaUSFDA inspection

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751